Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Eupraxia Pharmaceuticals Inc

EPRX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$6.72

▲ +0.75%

Market Cap $434.55M · Vol 63.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$434.55M

Small Cap

Div Yield

N/A

EPS Growth

+12.26%

YoY

RSI (14)

63.82

Momentum

Beta

N/A

vs Market

52W High

$9.31

27.82% below

52W Low

$5.04

33.33% above

Volume

63.14K

Avg 121.90K

P/B

7.47

Price-to-book

ROE

N/A

Return on equity

Free Float

85.38%

Public shares

Shariah Compliance8 STANDARDS

✗ Eupraxia Pharmaceuticals Inc (EPRX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EPRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.74%

+5.99%

-6.15%

-20.19%

YTD

-10.99%

+27.27%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-38,605,650.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-63.73% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	7.47
P/FCF	N/A
EPS Growth	+12.26%
Outstanding Shares	65.02M

Technical Indicators

50-Day SMA	$6.41
200-Day SMA	$7.05
RSI (14)	63.82
Beta	N/A
52-Week High	$9.31
52-Week Low	$5.04

Volume Today	63.14K
Avg Daily Volume (30D)	121.90K
Relative Volume	0.52x
Volatility (10D)	29.25
Volatility (30D)	58.75
Free Float	85.38%

Analyst Consensus

BUY

Current Price $6.72

Mean Target $16.44

52W Low$5.04 52W High$9.31

Current

Target

$5.04 $9.31

Current Analyst target

+144.71% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00Z83VS56

ISINCA29842P1053

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.